Inozyme Pharma, Inc.
NASDAQ:INZY
Overview | Financials
Company Name | Inozyme Pharma, Inc. |
Symbol | INZY |
Currency | USD |
Price | 1.38 |
Market Cap | 88,651,476 |
Dividend Yield | 0% |
52-week-range | 1.38 - 7.795 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Douglas A. Treco Ph.D. |
Website | https://www.inozyme.com |
An error occurred while fetching data.
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD